Study of ETX-636 for advanced solid tumors with PIK3CA mutation
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have spread or cannot be removed with surgery, and it has grown after at least one prior treatment.
- Your tumor must have a specific change in the PIK3CA gene, found in either your tumor tissue or blood test.
- You have at least one tumor that can be measured on scans or assessable disease.
- You are able to be up and around (ECOG score 0 or 1) and your organs are working well enough.
- If you have certain types of breast cancer (HR+/HER2-), you must have tried at least one CDK4/6 inhibitor and one hormone therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
This trial tests a new drug, ATX-898, alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.